- Home
- SXTP vs LIPO Comparison
SXTP vs LIPO Comparison
Compare SXTP & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- LIPO
- Stock Information
- Founded
- SXTP 2010
- LIPO 2005
- Country
- SXTP United States
- LIPO United States
- Employees
- SXTP N/A
- LIPO N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- LIPO Health Care
- Exchange
- SXTP Nasdaq
- LIPO Nasdaq
- Market Cap
- SXTP 2.7M
- LIPO 3.1M
- IPO Year
- SXTP 2023
- LIPO 2022
- Fundamental
- Price
- SXTP $2.95
- LIPO $2.65
- Analyst Decision
- SXTP Hold
- LIPO
- Analyst Count
- SXTP 1
- LIPO 0
- Target Price
- SXTP N/A
- LIPO N/A
- AVG Volume (30 Days)
- SXTP 4.8M
- LIPO 176.2K
- Earning Date
- SXTP 05-14-2025
- LIPO 05-08-2025
- Dividend Yield
- SXTP N/A
- LIPO N/A
- EPS Growth
- SXTP N/A
- LIPO N/A
- EPS
- SXTP N/A
- LIPO N/A
- Revenue
- SXTP $681,345.00
- LIPO $536,357.00
- Revenue This Year
- SXTP $95.50
- LIPO N/A
- Revenue Next Year
- SXTP $80.78
- LIPO N/A
- P/E Ratio
- SXTP N/A
- LIPO N/A
- Revenue Growth
- SXTP 168.70
- LIPO 19.29
- 52 Week Low
- SXTP $1.41
- LIPO $1.97
- 52 Week High
- SXTP $36.00
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- SXTP 56.45
- LIPO 57.23
- Support Level
- SXTP $2.48
- LIPO $2.25
- Resistance Level
- SXTP $3.45
- LIPO $2.44
- Average True Range (ATR)
- SXTP 0.70
- LIPO 0.22
- MACD
- SXTP 0.02
- LIPO 0.04
- Stochastic Oscillator
- SXTP 47.63
- LIPO 88.39
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.